Next 10 |
2024-04-25 07:56:55 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...
2024-04-25 07:10:53 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Non-GAAP EPS of $2....
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
2024-04-25 06:59:26 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Non-GAAP EPS of $2....
2024-04-25 06:32:23 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Q1 Earnings Preview...
Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, S...
2024-04-24 16:08:47 ET More on Immutep Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep Financial information for Immutep Read the full article on Seeking Alpha For further details see: Immutep reports promising ...
2024-04-24 10:03:42 ET Merck ( NYSE: MRK ) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market open.... Read the full article on Seeking Alpha For further details see: Merck Q1 Earnings Preview: Strong quarter expectations on the back ...
2024-04-23 12:40:36 ET Summary FDA approved ImmunityBio, Inc.'s ANKTIVA for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The global bladder cancer market could reach $11.5 billion by 20...
2024-04-23 11:45:16 ET Summary ImmunityBio, Inc.'s Anktiva approved by FDA for NMIBC, marking the company's first commercial product entry. Anktiva faces tough competition from existing treatments and promising therapies in the pipeline. ImmunityBio has financial resources for...
News, Short Squeeze, Breakout and More Instantly...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, S...